2024 ARCHIVES
Monday, August 19
Organizer's Welcome Remarks1:25 pm
Erin Kadelski, Associate Project Manager, Production, Cambridge Healthtech Institute
Introduction and Welcome
Richard M. Levenson, MD, Vice Chair for Strategic Technologies & Professor, Department of Pathology and Laboratory Medicine, University of California, Davis
Chairperson's Remarks
Farzad Fereidouni, PhD, Adjunct Assistant Professor, Pathology & Lab Medicine, University of California, Davis
AccessPath: A Low-Cost, Rugged System for Slide-Free Pathology Based on Computational Microscopy
Rebecca R. Richards-Kortum, PhD, Professor of Bioengineering, Malcolm Gillis University; Director, Rice 360° Institute for Global Health; Founder, Beyond Traditional Borders Undergraduate Global Health Program
AccessPath is an affordable system for immediate digital pathology of resected tumors. Tissue specimens are stained with inexpensive vital dyes and illuminated with UV excitation, localizing fluorescence emission to a thin surface layer. A custom optical phase mask and associated deep-learning algorithm jointly operate to extend depth-of-field (DOF) by >10X, resolving subcellular features in a DOF of 200 µm, allowing intact tissue specimens to be rapidly scanned without serial refocusing.
qOBM (Quantitative Oblique Back-Illumination Microscopy) for ex and in vivo Label-Free and Slide-Free Histology
Francisco (Paco) Robles, PhD, Associate Professor, Chair of Graduate Admissions and Recruiting, Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology & Emory University
qOBM is a recently developed label-free optical imaging technology that enables quantitative phase imaging and 3D refractive index tomography of thick tissues. The technology achieves high contrast imaging of cellular and subcellular structures to enable real-time ex and in vivo label-free and slide-free histology. In this presentation, I will describe the working principles of qOBM and show its potential for POC histology.
Non-Destructive 3D Pathology and Analysis for Precision Treatments
Jonathan T.C. Liu, PhD, Professor, Mechanical Engineering, University of Washington
In order to catalyze a digital pathology transformation to improve clinical decisions and patient outcomes, we are developing a novel technological approach that offers significant advantages over traditional “gold-standard” histopathology in terms of accuracy and throughput. First, we have developed an open-top light-sheet (OTLS) microscopy platform for slide-free 3D pathology of large clinical specimens, enabling whole biopsies and surgical specimens to be non-destructively imaged with an ease of use similar to a flat-bed document scanner. Next, using both hand-crafted and deep-learning AI techniques, we are quantifying 3D spatial and molecular biomarkers for enhanced clinical decision support, such as for prognosticating patient outcomes (indolent vs. aggressive disease) and to guide resection procedures.
Real-Time Structured Light and Computational Microscopy for Onsite Pathology
J. Quincy Brown, PhD, Associate Professor, Department of Biomedical Engineering, Tulane University
Structured illumination microscopy (SIM) has a number of compelling applications in direct-to-digital onsite pathology, including large-area rapid 2D imaging for core biopsy and whole-resection tumor margin assessment, and rapid nondestructive cytologic imaging. Additionally, the combination of emerging concepts in computational microscopy, image analysis, and artificial intelligence may accelerate or ease translational burdens for these technologies. We will discuss these topics and more in the context of point-of-care histology for diagnosis and treatment of prostate cancer.
FIBI (Fluorescence Imitating Brightfield Imaging): Replacing Whole-Slide Imaging with No-Slide Imaging
Our lab at UC Davis has developed a new imaging method, FIBI (Fluorescence Imitating Brightfield Imaging), for the histopathological assessment of freshly excised or fixed specimens. This method generates diagnostic-grade images without requiring previous preparation of a glass slide. FIBI images are generated by virtual back-illumination of a stained tissue surface of stained tissue, using 405 nm LED illumination configured in epifluorescence mode and conventional microscope objectives. The resulting images immediately resemble familiar glass-slide-based brightfield histology. We will discuss this technology's utility for various applications, including rapid onsite evaluation (ROSE), point-of-care diagnostics, intraoperative margin assessment and global deployment.
Refreshment Break in the Exhibit Hall with Poster Viewing3:15 pm
Reflectance Confocal Microscopy of Skin Cancers: Imaging Noninvasively Guides Diagnosis, Treatment, and Management
Milind Rajadhyaksha, PhD, Member of Faculty, Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center
Reflectance confocal microscopy images cellular patterns and morphology in human skin and detects skin cancers with high sensitivity and specificity. Following two decades of development and clinical trials, RCM imaging of skin was granted reimbursement codes in 2016. The imaging is now being adopted and advancing into routine use for noninvasively guiding diagnosis, treatment, and management of skin cancers. This talk will present a critical overview of this field.
Light Absorption, Scattering, and Emission (LASE) Microscopy for Virtual Histology
Roger Zemp, PhD, Associate Professor, Electrical & Computer Engineering, University of Alberta
Methods for intra-operative determination of surgical margins via ex-vivo thick tissue analysis could lead to more successful cancer surgeries. Multiple labeled and label-free microscopy methods have been proposed with this objective, yet none has emerged with sufficient histological realism, speed, and utility to change clinical practice. I will discuss recent developments in bringing ultraviolet absorption, scattering, and autofluorescence emission contrast into a single imaging platform. Absorption imaging is achieved using photoacoustic imaging, photoacoustic remote sensing, or negative contrast in autofluorescence imaging. Autofluorescence in multiple optical bands enable simultaneous imaging of tissue optical redox ratio for mapping metabolic activity, co-registered with virtual histology. These developments, coupled with advances in deep learning, have enabled realistic virtual histology capabilities with clinically acceptable sensitivity and specificity compared to gold-standard H&E histology. Moreover, scan rates as high as 7min/cm2 with 400nm resolution were achieved with room for significant speedups in future work.
AI in Point-of-Care Histology: Opportunities and Obstacles
Heather D. Couture, PhD, Consultant & Researcher, Pixel Scientia Labs
From expedited diagnoses to enhanced patient care, AI presents revolutionary prospects in point-of-care histology. However, challenges such as scarce labeled data and variations across devices and facilities must be addressed for robust solutions. In this talk, I’ll delve into some promising uses for AI, demonstrate the primary obstacles that medical device developers should be prepared for, and propose solutions that can enable AI to transform point-of-care histology practices.
Panel Discussion with Speakers
Welcome Reception in the Exhibit Hall with Poster Viewing5:15 pm
Close of POC Histology Special Forum6:30 pm
Tuesday, August 20
FDA Perspectives: Trends and Challenges
Courtney H. Lias, PhD, Director, OHT7: Office of in vitro Diagnostic Devices, United States Food and Drug Administration (FDA)
Laboratory-Developed Tests: Proposed Rule, Reclassification Activities, Potential Impact, and Path Forward
B. Melina Cimler, PhD, CEO & Founder, PandiaDx LLC
Laboratory-developed tests (LDTs) are an important part of healthcare. The FDA released a final rule on May 6, 2024, to amend the FDA’s regulations to make explicit that IVDs are devices under the Federal FD&C Act, including when the manufacturer of the IVD is a laboratory. FDA issued a policy under which the FDA intends to provide greater oversight of LDTs, through a phaseout of its general enforcement discretion approach.
This panel brings together stakeholders to:
Stefan Burde, PhD, Director, Global Strategic Business Development, TÜV SÜD America, Inc.
Girish Putcha, MD, PhD, Principal & Founder, Precision Medicine & Diagnostics
Lakshman Ramamurthy, PhD, Vice President, Regulatory Affairs, GRAIL
Anna Scrimenti, Associate Director, Public Policy & Advocacy, Association for Molecular Pathology
Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own1:10 pm
2025 Conference Programs
Enabling Point-of-Care Diagnostics
Advanced Diagnostics for Infectious Disease
Coverage and Reimbursement for Advanced Diagnostics
Clinical Biomarkers and Companion Diagnostics
Early Cancer Surveillance
Liquid Biopsy for Disease Management